A recent PBPK publication evaluated the impact of elevated IL‐6 on CYP3A substrates in patients with COVID‐19 predicted DDI liability under the highest observed IL‐6 concentration of 4462 pg/mL, which might provide an additional dataset for model validation.13 This evidence concerns the gene IL6 and COVID-19.